publication date: Mar. 31, 2017

In Brief Carlo Croce to receive 2017 AACR Margaret Foti Award for leadership, achievements in research

Carlo Croce will receive the 11th Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research during the AACR Annual Meeting 2017, to be held April 1-5, in Washington.

Croce is the director of the Institute of Genetics and director of the human cancer genetics program at The Ohio State University Comprehensive Cancer Center and professor and chair of the Department of Molecular Virology, Immunology, and Medical Genetics at The Ohio State University School of Medicine in Columbus. AACR said he is being recognized for “consistent and long-standing impact on the translation of fundamental cancer mechanisms to clinical applications.”

Croce’s work focuses in part on druggable targets. According to AACR, he has “translated chromosomal translocation breakpoints to strategies for cancer prevention, early detection, and therapy.”

The Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research was established in 2007 to recognize researchers whose “leadership and extraordinary achievements in cancer research have had a major impact on the field.”

Croce’s research has established genetic links to a variety of cancers including Burkitt lymphoma, T-cell lymphoma, and acute leukemia. His discoveries have shown that chromosomal abnormalities such as translocations are capable of contributing to both cancer … Continue reading Carlo Croce to receive 2017 AACR Margaret Foti Award for leadership, achievements in research

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.